Perrigo Completes Divestiture Of Generic Rx Business For $1.55 Billion
Perrigo Company plc (NYSE: PRGO) has successfully completed the sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion. This strategic divestiture marks a significant milestone in Perrigo's transformation into a leading global consumer self-care entity. CEO Murray S. Kessler emphasized the company's commitment to enhancing self-care product offerings, which has positioned Perrigo as the largest store brand OTC player in the U.S. and a top OTC company in Europe. The company aims to leverage its resources for future growth.
- Completed sale of Generic Rx Pharmaceuticals for $1.55 billion, enhancing liquidity.
- Strengthens position as a leading global consumer self-care company.
- Perrigo is the largest store brand OTC player in the U.S. with over 9,000 SKUs.
- None.
DUBLIN, July 6, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for
Perrigo CEO and President Murray S. Kessler commented, "Closing this transaction was another important milestone for Perrigo's transformation. We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality – To make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company's future."
Kessler concluded, "I would like to thank the Rx team for their dedication throughout this process and I am confident that they will continue to be successful in their mission of developing, manufacturing and distributing high quality, affordable healthcare products."
About Perrigo
Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. Visit Perrigo online at www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and supply chain impacts on the Company's business; general economic, credit, and market conditions; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment (the "NoA") issued by the Irish tax authority and the draft and final Notices of Proposed Assessment ("NOPAs") issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information and litigation relating to uncertain tax positions, including the NoA and the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the success of the sale of the Rx business, including the ability to achieve the expected benefits thereof, the risk that potential costs or liabilities incurred or retained in connection with the transaction may exceed the Company's estimates or adversely affect the Company's business or operations; the consummation and success of other announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to our appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2020, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-completes-divestiture-of-generic-rx-business-for-1-55-billion-301326359.html
SOURCE Perrigo Company plc
FAQ
What was the amount of the sale of Perrigo's Generic Rx Pharmaceuticals business?
Who purchased Perrigo's Generic Rx Pharmaceuticals business?
How does the sale of the Generic Rx Pharmaceuticals business affect Perrigo's focus?
What is Perrigo's position in the OTC market after the divestiture?
When was the sale of Perrigo’s Generic Rx Pharmaceuticals business completed?
